Initiation of prandial insulin therapy with air inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial

Diabetes Technology and Therapeutics

Volumn 11, Issue SUPPL. 2, 2009, Pages

  Gross, Jorge L ^a   Nakano, Masako ^b   Colon Vega, Gildred ^c   Ortiz Carasquillo, Ramon ^d   Ferguson, Jeffrey A ^b   Althouse, Sandra ^b   Tobian, Janet A ^b   Berclaz, Pierre Yves ^b   Milicevic, Zvonko ^e  

^a Centro de Pesquisas em Diabetes   (Brazil)

^b ELI LILLY AND COMPANY   (United States)

^c American Telemedicine Center   (Puerto Rico)

^d Manati Medical Center   (Puerto Rico)

^e Eli Lilly Regional Operations   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AIR INHALED INSULIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONIC CLONIC SEIZURE;

ADMINISTRATION, INHALATION; AGED; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; MALE; METFORMIN; MIDDLE AGED; PATIENT SELECTION; VITAL CAPACITY;

EID: 70349453892     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0037     Document Type: Article

References (25)

1. Hayes RP, Bowman L, Monahan PO, Marrero DG, McHorney CA: Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ 2006;32:404-414
2. Hayes RP, Fitzgerald JT, Jacober SJ: Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008;62:860-868
3. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L; The International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679
4. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV: Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem 202. Diabetes Care 2005;28:2543-2545
5. Rosenstock J, Muchmore D, Swanson D, Schmitke J: AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. Expert Rev Med Devices 2007;4: 683-692
6. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-2362
7. Quattrin T: Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes. Expert Opin Pharmacother 2004;5: 2597-2604
8. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peñ a A, Muchmore DB: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49:891-899
9. Bradley C: The Diabetes Treatment Satisfaction Questionnaire (DTSQ). In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Newark, NJ: Harwood Academic Publishers, 1994:111-132
10. Marshall T, Silva S, Hayes C: Validation of the Insulin Delivery System Questionnaire (IDSQ) in patients with type 2 diabetes. J Diabetes Sci Technol 2007;1:A109
11. Garg SK, Mathieu C, Rais N, Gao H, Tobian JA, Gates JR, Ferguson JA, Webb DM, Berclaz P-Y: Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol Ther 2009;11(Suppl 2):S-5-S-16
12. Moxness M, Foey J, Finco-Kent D, Bedian V, Krasner A, Kawabata T: Development and validation of radioligand binding assays to measure total, IgA, IgE, IgG, and IgM insulin antibodies in human serum. Ann N Y Acad Sci 2003;1005:265-268
13. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: General considerations for lung function testing. Eur Respir J 2005;26:153-161
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005;26:319-338
15. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-522
16. Akritas MD, Arnold SF, Brunner E: Nonparametric hypotheses and rank statistics for unbalanced factorial designs. J Am Stat Assoc 1997;92:258-265
17. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084
18. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730
19. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265
20. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
21. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A: Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90:3287-3294
22. Comulada AL, Renard E, Nakano, M, Rais N, Mao X, Webb DM, Milicevic Z: Efficacy and safety of Air inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. Diabetes Technol Ther 2009;11(Suppl 2):S-17-S-25
23. Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM: Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR Insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technol Ther 2009;11(Suppl 2):S-63- S-73
24. Hegewald M, Crapo RO, Jensen RL: Pulmonary function changes related to acute and chronic administration of inhaled insulin. Diabetes Technol Ther 2007;9(Suppl): S-93-S-101
25. Bindra S, Cefalu WT: Exubera. Inhale therapeutic systems. Curr Opin Investig Drugs 2002;3:758-762